Huangshi Central Hospital
12
0
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases
Role: collaborator
Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction
Role: collaborator
Tirofiban After Successful MT Recanalization in AIS
Role: collaborator
ICSI Versus Conventional IVF in Couples With Unexplained Infertility
Role: collaborator
Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression
Role: collaborator
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
Role: collaborator
Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer
Role: collaborator
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
Role: collaborator
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Role: collaborator
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Role: collaborator
Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules
Role: collaborator
Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules
Role: collaborator
All 12 trials loaded